Pall Torfi Onundarson
Could the Fiix normalized ratio (Fiix PT) save taxpayer´s money and insurance premiums?
The answer is yes. Because the Fiix-PT improves the effectiveness of warfarin markedly without reducing safety. See the publications list for the arguments behind this statement.
The cost of drugs for heart disease in the UK has increased 9-fold between 2014 to 2020, mainly due to switch from warfarin to DOAC drugs (see https://bylinetimes.com/2022/05/10/prescription-spend-on-heart-disease-increases-by-half-a-billion-in-four-years/ ).
The DOACs have similar effectiveness as traditionally monitored warfarin but cause somewhat less intracranial bleeding albeit fortunately rarely. But DOAC treatment is much more expensive, even when clinic visits and monitoring costs of VKAs are included.
As the effectiveness of warfarin is improved using the new monitoring method (Fiix-PT based Fiix-NR), should societies consider changing guidelines back in favor of warfarin over DOACs? Or at least in favor of replacing PT-INR monitoring of VKAs with the more effective monitoring method?
We contend that if PT-INR monitoring og VKAs would be replaced by Fiix-NR, patient outcome and convenience would be improved - and that this would save taxpayer´s money and health insurance premiums. Less thromboembolism, less permanent paralysis, reduced disability. The mony could then be better spent elsewhere (or taxes and premiums reduced).